PPT-The Resource Based View of the Firm (RBV)

B290 The object of strategic analysis Explain why a firm or a group of firms is making above normal returns ie More than their long run average costs Two possible explanations Its something to do with the industry in which they operate. dans les génotypes 1b naïfs de traitement . (1). ABT-450/r/ABT-267 : 150 mg/100 mg/25 mg x 1/j. ABT-333 : 250 mg x 2/j. RBV : 1 000 mg si poids < 75 kg, 1 200 mg si ≥ 75 kg . Étude de phase III réalisée chez des patients . Mark Sulkowski, MD . Professor of Medicine. Medical Director, Viral Hepatitis Center. Divisions of Infectious Diseases and Gastroenterology/ Hepatology. Johns Hopkins Medical Institutions. Baltimore Maryland USA. -Ritonavir. -Ombitasvir . + Dasabuvir) . + RBV in . GT1. SAPPHIRE-II. Phase . 3. Treatment. . Experienced. Zeuzem. S, . et al. N . Engl. J Med. . 2014;370:1604-14.. Source: . Zeuzem. S, et al. N . Design. C-SCAPE . Study. : . grazoprevir. ± . elbasvir. ± RBV . in . genotypes. 2, 4, 5 or 6. Treatment-naïve . Genotype 2. , 4, 5, 6. Non-cirrhotic, . HCV . monoinfected. Brown . A. . . J . Hepatol. OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + RBV. Randomisation*. 1 : . 1. Open-label. 18-70 years. HCV genotype 1. HCV RNA ≥ 10,000 IU/ml. Naïve or pre-treated with PEG-IFN + RBV. HIV infection, on ATV/. HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAILAND. When to Treat HCV. . HCV Direct-Acting . Antivirals. (. DAAs. ) in . development. . OVERVIEW. Know your epidemic: what matters. OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + RBV. Randomisation*. 1 : . 1. Open-label. 18-70 years. HCV genotype 1. HCV RNA ≥ 10,000 IU/ml. Naïve or pre-treated with PEG-IFN + RBV. HIV infection, on ATV/. RBV . versus. . PEG alfa-. 2a . versus. INF + RBV . APRICOT STUDY. Phase 3. Treatment. . Naïve, Chronic HCV and HIV. Torriani. FJ, . et. al. N . Engl. J Med. . 2004;351:438-50. . PEG . + . RBV . Randomisation. Open-label. W8. * Liver biopsy or . Fibroscan. . > 12.5 . kPa. or . Fibrotest. . . >. 0.75 + APRI . > 2. Objective. Primary endpoint: SVR. 12 . (HCV RNA < 15 IU/mL), full analysis set . N = 69. >. 18 years. Failure to SOF/VEL . or SOF/VEL + VOX . (LEPTON study). Any genotype. Compensated cirrhosis allowed. No HBV or HIV co-infection. Open-label. SOF/VEL: 400/100 mg FDC QD ; RBV: weight based in twice daily dose . Randomisation*. Open-label. >. 18 years. HCV genotype 1. HCV RNA ≥ 10,000 IU. /ml. Treatment naïve and . compensated cirrhosis (Child-Pugh A). or. Null responders to previous PEG-IFN + RBV, with or without cirrhosis. SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label. BOSON . Study. : SOF + RBV . +. PEG-IFN . for genotypes 2 and 3. ≥ 18 years. Chronic HCV infection. Genotype 2, treatment-experienced with cirrhosis. Gene LeSage, MD, FACP, AGAF. Objectives. HCV epidemiology, risk factors, diagnosis and prognosis. Interferon (IFN) and Ribavirin (RBV) based therapy. Direct acting anti-viral . (. DAA) therapies. HCV Epidemiology. La gamme de thé MORPHEE vise toute générations recherchant le sommeil paisible tant désiré et non procuré par tout types de médicaments. Essentiellement composé de feuille de morphine, ce thé vous assurera d’un rétablissement digne d’un voyage sur .